The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma
Open accessAbstract
Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods: S1505 (NCT02562716) was a randomized phase II study of perioperative chemotherapy with mFOLFIRINOX (Arm 1) or gemcitabine/nab-paclitaxel (Arm 2). Measured parameters included resection rate, margin positivity, pathologic response, and toxicity. Results: Between 2015 and 2018, 147 patients were randomized. Of these, 44 (30%) were deemed ineligible (43 by central review). Of the 103 eligible patients, 77 (76%) completed preoperative therapy and underwent surgery; reasons patients did not undergo surgery included toxicity related to preoperative therapy (n = 9), progression (n = 9), or other (n = 7). Of the 77, 73 (95%) underwent successful resection; 21 (29%) required vascular reconstruction, 62 (85%) had negative (R0) margins, and 24 (33%) had a complete or major pathologic response to therapy. The grade 3–5 postoperative complication rate was 16%. Of the 73 patients completing surgery, 57 (78%) started and 46 (63%) completed postoperative therapy. This study represents the first prospective trial evaluating modern systemic therapy delivered in a neoadjuvant/perioperative format for resectable PDA. Conclusions: We have demonstrated: (1) Based on the high percentage of enrolled, but ineligible patients, it is clear that adherence to strict definitions of resectable PDA is challenging; (2) Patients can tolerate modern systemic therapy and undergo successful surgical resection without prohibitive perioperative complications; (3) Completion of adjuvant therapy in the perioperative format is difficult; (4) Major pathologic response rate of 33% is encouraging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationFOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874 · cited 2×
“Annals of Surgery Volume 272, Number 3, September 2020 P rospective clinical trials have validated adjuvant therapy as a treatment modality that improves overall survival (OS) in patients with resectable pancreas cancer.(1,2) Unfortunately, the great majority of patients with pancreas cancer have occult systemic disea…”
BackgroundDistant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Cited by
Neoadjuvant therapy for pancreatic cancer
Springfeld, C., Ferrone, C. R., Katz, M. H. G., Philip, P. A., Hong, T. S., Hackert, T., Büchler, M. W., & Neoptolemos, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00746-1 · Cited by 377
Self-citationSohal, D. P. S., Duong, M., Ahmad, S. A., Gandhi, N. S., Beg, M. S., Wang-Gillam, A., Wade, J. L., Chiorean, E. G., Guthrie, K. A., Lowy, A. M., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7328 · Cited by 302
Self-citationEcker, B. L., Court, C. M., Janssen, Q. P., Tao, A. J., D’Angelica, M. I., Drebin, J. A., Gonen, M., O’Reilly, E. M., Jarnagin, W. R., Wei, A. C., et al. (2022) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000000212 · Cited by 13
Metadata
- Authors
- Ahmad, S. A., Duong, M., Sohal, D. P. S., Gandhi, N. S., Beg, M. S., Wang-Gillam, A., Wade, J. L., Chiorean, E. G., Guthrie, K. A., Lowy, A. M., Philip, P. A., & Hochster, H. S.
- Venue
- Annals of Surgery
- Published
- 2020-07-24
- Volume
- 272
- Issue
- 3
- Pages
- 481-486
- ISSN
- 0003-4932 (ISSN-L)
- 1528-1140
- OpenAlex
- W3047136679
- Cited by
- 238
- References
- 4
- FWCI
- 12.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma. https://app.cochat.ai/papers/10.1097/sla.0000000000004155
- The paper
- Ahmad, S. A., Duong, M., Sohal, D. P. S., Gandhi, N. S., Beg, M. S., Wang-Gillam, A., Wade, J. L., Chiorean, E. G., Guthrie, K. A., Lowy, A. M., Philip, P. A., & Hochster, H. S. (2020). Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma. Annals of Surgery. https://doi.org/10.1097/sla.0000000000004155
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.